Chemours Current Valuation

CC -- USA Stock  

Earning Report: November 4, 2019  

Chemours current-valuation fundamental analysis lookup allows you to check this and other indicators for Chemours Company or any other equity instrument. You can also select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please check also Equity Screeners to view more equity screening tools

Chemours Current Valuation Analysis

Enterprise Value is a firm valuation proxy that approximates current market value of a company. It is typically used to determine takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that company has on its balance sheet. When takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value 
Market Cap + Debt 
More About Current Valuation | All Equity Analysis
Chemours Current Valuation  =
6.57 B
Chemours ValuationFundamentalsBuy or Sell

Chemours Current Valuation Over Time Pattern

 Chemours Enterprise Value 

About Current Valuation

Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Compare to competition
Accumulated Other Comprehensive Income
In accordance with recently published financial statements Chemours Company has Current Valuation of 6.57 B. This is 42.42% lower than that of the Basic Materials sector, and 78.67% lower than that of Specialty Chemicals industry, The Current Valuation for all stocks is 60.48% higher than the company.

Did you try this?

Run Equity Search Now


Equity Search

Search for activelly-traded equities including funds and ETFs from over 30 global markets
All  Next Launch Module

Chemours current financial ratios